Kewaunee Scientific (KEQU) Return on Equity ROE from the first quarter 2026 to first quarter 2026 and annually, average high and low, overall ranking from Jul 31 2026 to Jul 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Kewaunee Scientific Corporation  (NASDAQ: KEQU)

Kewaunee Scientific's ROE per quarter

Return on Equity, Quarterly Results, Trends, Rankings, Statistics


What is ROE for Kewaunee Scientific in the first quarter 2026?
Kewaunee Scientific Corporation achieved a return on average equity (ROE) of 12.61 % in its first quarter 2026, this is above KEQU's average return on equity of 8.09%.
Kewaunee Scientific Corporation shareholder's equity over the 12 months ending in its first quarter 2026 are valued at $73 million

ROE decreased relative to the period ending , due to the decline in net income.

Within the Laboratory Analytical Instruments industry 3 other companies had a higher return on equity. While return on equity, the total ranking has deteriorated compared to the fourth quarter 2026 from 889 to 899.

What is ROE?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Equity (Jul 31 2026)
I. Quarter		 (Apr 30 2026)
IV. Quarter		 (Jan 31 2026)
III. Quarter		 (Oct 31 2025)
II. Quarter		 (Jul 31 2025)
I. Quarter
Y / Y Equity Change 15.12 % 19.17 % 17.85 % 17.74 % -
Y / Y Net Income Change -41.66 % -25.37 % -22.2 % -15.82 % 41.15 %
Net Income (TTM) in Millions 9 10 12 12 13
Return On Equity (TTM) 12.61 % 14.95 % 17.52 % 18.68 % 20.24 %
KEQU's Total Ranking # 899 # 889 # 708 # 671 # 571
Equity (TTM) in Millions 77 77 66 70 67
Seq. Equity Change 0.53 % 15.95 % -5.16 % 4.14 % 4.07 %
Seq. Net Income Change -50.08 % 243.12 % -57.6 % -19.66 % -36.14 %

Back to KEQU Management Effectiveness >> KEQU's 5 Years Annual ROE >> Compare KEQU ROE to its Competitors
Return On Equity Company Ranking
Within: No.
Industry # 4
Sector # 133
Overall # 899

Return On Equity Statistics
High Average Low
42.26 %
8.09 %
-22.21 %
(Apr 30 2024)   (Jan 31 2022)





KEQU Annual Return On Equity (Apr 30 2026)
2026		 (Apr 30 2025)
2025		 (Apr 30 2024)
2024		 (Apr 30 2023)
2023		 (Apr 30 2022)
2022
Total Equity in Millions 77 66 56 38 36
Y / Y Equity Change 15.95 % 17.85 % 46.05 % 6.37 % -12.79 %
Net Income in Millions 10 12 19 1 -6
Y / Y Net Income Change -9.65 % -39.22 % 1302.28 % - -
Return On Equity 13.62 % 17.49 % 33.9 % 3.53 % -16.59 %

Back to KEQU Management Effectiveness >> KEQU's 5 Years Annual ROE >> Compare KEQU ROE to its Competitors




Annual Roe Comment
In 2026 ROE decreased compared to the previous year to 13.62 %, due to deterioration of net income.


More Return On Equity Ratios
Laboratory Analytical Instruments Industry Roe Trends and Statistics
Healthcare Sector Return On Equity Statistics
KEQU's' Return on Equity at Yahoo Finance
KEQU's Roe Ratio versus Laboratory Analytical Instruments Industry, Healthcare Sector and overall Market
Highest Ranking Return On Equity
Lowest Ranking Return On Equity
Subscribers only: Roe for KEQU's Competitors
Subscribers only: Roe for Kewaunee Scientific's Suppliers
Subscribers only: Return On Equity for KEQU's Customers




Companies with similar Return On Equity at Jul 31 2026, within Healthcare Sector ROE
Transmedics Group Inc   33.37 %
Arcutis Biotherapeutics Inc   32.92 %
Caredx Inc   32.81 %
Zevra Therapeutics Inc   32.56 %
Acadia Pharmaceuticals Inc   32.39 %
Pro dex Inc   31.96 %
Protalix Biotherapeutics inc   31.61 %
Illumina Inc   31.08 %
Innoviva Inc   30.03 %
Phibro Animal Health Corporation  29.66 %
Chemed Corporation  29.45 %
Solventum Corporation  28.96 %
Pacs Group Inc   27.00 %
Sotera Health Company  26.75 %
Insulet Corporation  26.69 %
Bioventus Inc   25.96 %
Johnson and Johnson  25.74 %
Encompass Health Corporation  25.52 %
Resmed Inc   24.21 %
Healthcare Services Group Inc   24.12 %
Electromed Inc   23.65 %
Iradimed Corporation  23.45 %
Vertex Pharmaceuticals Inc  23.31 %
Lantheus Holdings Inc   23.27 %
Msa Safety Inc  23.15 %
Prestige Consumer Healthcare Inc   21.77 %
Jazz Pharmaceuticals Plc  21.37 %
Neurocrine Biosciences Inc   21.13 %
Universal Health Services Inc   20.89 %
Puma Biotechnology Inc   20.85 %

Date modified: 2026-09-12T18:36:58+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.